Frank E Thomas bought LRMR once, on Feb 27, 2026

Frank E. Thomas is a biotechnology executive and corporate director who serves on the board of Larimar Therapeutics, Inc., a role he has held since May 2020 following prior service on the Zafgen, Inc. board beginning in June 2014.( In February 2026, he reported an open‑market style purchase of 5,000 shares of Larimar Therapeutics common stock at $5.00 per share in connection with an underwritten offering, increasing his direct ownership to 7,000 shares and confirming his status as an insider director at the company.(

Thomas is Chief Operating Officer and Chief Financial Officer of Orchard Therapeutics, having held those roles since January 2020 after previously serving as the company’s Chief Financial Officer and Chief Business Officer from 2018 to 2020.( Earlier, he was President and Chief Operating Officer of AMAG Pharmaceuticals (2015–2017), and before that Executive Vice President and COO (2012–2015) and Executive Vice President, CFO and Treasurer (2011–2012).( His prior executive experience includes leadership roles at Molecular Biometrics, Critical Therapeutics—where he was CEO and a director from 2006 to 2008—and Esperion Therapeutics.( Thomas has served on the board of Spero Therapeutics since July 2017 and previously sat on the board of the Massachusetts Biotechnology Council from 2007 to 2015.( He holds a B.B.A. from the University of Michigan, Ann Arbor.(

Written by Perplexity from public sources.